​

Abivax (ABVX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

ABVX Stock Forecast

Abivax (ABVX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $120.00, with a high of $150.00 and a low of $74.00. This represents a 27.32% increase from the last price of $94.25.

- $30 $60 $90 $120 $150 High: $150 Avg: $120 Low: $74 Last Closed Price: $94.25

ABVX Stock Rating

Abivax stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

ABVX Price Target Upside V Benchmarks

TypeNameUpside
StockAbivax27.32%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts347
Avg Price Target$137.33$131.50$92.14
Last Closing Price$94.25$94.25$94.25
Upside/Downside45.71%39.52%-2.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2544---8
Sep, 2543---7
Aug, 2543---7
Jul, 25341--8
Jun, 25241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2025Etzer DaroutBarclays$142.00$93.7751.43%50.66%
Oct 10, 2025Guggenheim$150.00$90.6165.54%59.15%
Oct 06, 2025BTIG$120.00$86.6738.46%27.32%
Sep 25, 2025JMP Securities$114.00$82.0039.02%20.95%
Jul 23, 2025Thomas SmithLeerink Partners$74.00$63.7416.10%-21.49%
Jul 18, 2025Jason ButlerJMP Securities$33.00$10.34219.15%-64.99%
Mar 20, 2025Morgan Stanley$12.00$7.0669.97%-87.27%
Sep 10, 2024Alexander PotterPiper Sandler$42.00$11.99250.29%-55.44%
May 20, 2024Julian HarrisonBTIG$43.00$13.64215.25%-54.38%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2025BarclaysOverweightinitialise
Oct 10, 2025GuggenheimBuyBuyhold
Oct 06, 2025BTIGBuyBuyhold
Sep 25, 2025CitigroupOutperformOutperformhold
Sep 12, 2025Morgan StanleyOverweightOverweighthold
Jul 23, 2025Leerink PartnersOutperformOutperformhold
Jul 18, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 10, 2024Piper SandlerOverweightOverweighthold
Jul 29, 2024LaidlawBuyinitialise
May 20, 2024BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.13$-2.35-----
Avg Forecast$-2.83$-2.55$-1.98$-2.73$-2.63$-2.32$-1.53$-0.52
High Forecast$-1.53$-0.86$-1.79$-2.57$-2.34$-0.79$-0.52$-0.18
Low Forecast$-4.43$-4.15$-2.15$-2.92$-2.98$-3.78$-2.50$-0.85
Surprise %-12.72%22.75%18.69%-----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$37.00K-------
Avg Forecast$649.45K$1.65M$431.20K$7.27M$5.53M$3.83M$134.18M$283.42M
High Forecast$933.47K$2.44M$447.40K$9.31M$8.20M$5.68M$199.08M$420.53M
Low Forecast$420.50K$809.12K$414.09K$6.21M$2.72M$1.88M$65.96M$139.34M
Surprise %-94.30%-------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-41.36M$-69.85M$-147.40M-----
Avg Forecast$-121.73M$-109.67M$-85.06M$-117.57M$-113.10M$-100.04M$-66.03M$-22.59M
High Forecast$-65.94M$-37.19M$-77.30M$-110.73M$-100.84M$-33.92M$-22.39M$-7.66M
Low Forecast$-190.93M$-178.65M$-92.47M$-125.63M$-128.52M$-162.95M$-107.56M$-36.80M
Surprise %-66.03%-36.32%73.29%-----

ABVX Forecast FAQ

Is Abivax stock a buy?

Abivax stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Abivax is a favorable investment for most analysts.

What is Abivax's price target?

Abivax's price target, set by 7 Wall Street analysts, averages $120 over the next 12 months. The price target range spans from $74 at the low end to $150 at the high end, suggesting a potential 27.32% change from the previous closing price of $94.25.

How does Abivax stock forecast compare to its benchmarks?

Abivax's stock forecast shows a 27.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Abivax over the past three months?

  • October 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Abivax’s EPS forecast?

Abivax's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.73, marking a 16.17% increase from the reported $-2.35 in 2023. Estimates for the following years are $-2.63 in 2025, $-2.32 in 2026, $-1.53 in 2027, and $-0.52 in 2028.

What is Abivax’s revenue forecast?

Abivax's average annual revenue forecast for its fiscal year ending in December 2024 is $7.27M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $5.53M, followed by $3.83M for 2026, $134.18M for 2027, and $283.42M for 2028.

What is Abivax’s net income forecast?

Abivax's net income forecast for the fiscal year ending in December 2024 stands at $-118M, representing a -20.23% decrease from the reported $-147M in 2023. Projections indicate $-113M in 2025, $-100M in 2026, $-66.034M in 2027, and $-22.591M in 2028.